Details for Patent: 10,414,773
✉ Email this page to a colleague
Which drugs does patent 10,414,773 protect, and when does it expire?
Patent 10,414,773 protects UKONIQ and is included in one NDA.
This patent has thirteen patent family members in nine countries.
Summary for Patent: 10,414,773
| Title: | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations |
| Abstract: | The present invention relates to solid state forms of a p-toluenesulfonic acid salt (PTSA) of the selective PI3K delta inhibitor (S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrim- idin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one (TGR-1202). The present invention also relates to methods of preparing the same, pharmaceutical compositions containing them, and methods of treating a PI3K kinase mediated disease or disorder, such as cancer, by administering the same. |
| Inventor(s): | Vakkalanka; Swaroop K. (La Chaux-de-Fonds, CH) |
| Assignee: | RHIZEN PHARMACEUTICALS SA (La Chaux-de-Fonds, CH) |
| Application Number: | 15/950,606 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; |
Drugs Protected by US Patent 10,414,773
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tg Theraps | UKONIQ | umbralisib tosylate | TABLET;ORAL | 213176-001 | Feb 5, 2021 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED REGIMEN | ⤷ Try a Trial | ||
| Tg Theraps | UKONIQ | umbralisib tosylate | TABLET;ORAL | 213176-001 | Feb 5, 2021 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL) WHO HAVE RECEIVED AT LEAST THREE PRIOR LINES OF SYSTEMIC THERAPY | ⤷ Try a Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 10,414,773
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| India | 2596/CHE/2014 | May 27, 2014 |
International Family Members for US Patent 10,414,773
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2015265542 | ⤷ Try a Trial | |||
| Canada | 2949932 | ⤷ Try a Trial | |||
| China | 106661030 | ⤷ Try a Trial | |||
| China | 111635406 | ⤷ Try a Trial | |||
| Eurasian Patent Organization | 032506 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
